Sanofi (SNY) Q1 2026 earnings review
Double-Digit Topline Growth Masks Profit-Sharing Margin Squeeze
Sanofi's Q1 2026 results reflect a biopharma engine running hot, with sales accelerating to 13.6% growth at constant exchange rates (CER). Dupixent breached €4B again, and the new launch portfolio grew nearly 50%. However, beneath the robust volume growth, earnings quality is facing structural friction. Business EPS grew 14.0% at CER, but Business Operating Income (BOI) margins compressed by 0.7 points. The culprit is a massive 62% surge in Regeneron profit-sharing expenses. With full-year guidance calling for high single-digit sales growth, Q1's hyper-growth is expected to decelerate, placing intense focus on cost discipline in the upcoming quarters.
🐂 Bull Case
Dupixent continues to scale relentlessly (+30.8% CER), paired with recent pharma launches soaring nearly 50%. This high-margin specialty care transition is easily neutralizing legacy declines.
The Dynavax acquisition closed smoothly, with Heplisav-B immediately contributing to an otherwise stagnant U.S. vaccine segment, solidifying Sanofi's shift toward older adult demographics.
🐻 Bear Case
Other operating expenses jumped 62.4% (CER), heavily driven by Regeneron profit-sharing. This structural cost is eroding operating leverage and preventing gross margin gains from flowing to the bottom line.
Vaccine growth decelerated to a meager 2.1% (CER), hampered by a high basis of comparison for Beyfortus in the U.S. and severe demographic headwinds for pediatric vaccines in China.
⚖️ Verdict: 🟢
Bullish. The core volume growth of Sanofi's innovative portfolio remains spectacular. While the Regeneron margin squeeze is a genuine concern, the sheer scale of the top-line beat provides ample cushion to absorb these partnership costs.
Key Themes
Dupixent: Stable and Relentless Scale
Dupixent sales reached €4.17B, marking a stable, powerful 30.8% YoY growth at CER. Growth is largely volume-driven across approved indications. U.S. sales jumped 35.9%, partly flattered by a favorable basis of comparison, but underlying demand remains robust across AD, COPD, and asthma. The asset retains a commanding market position, acting as the primary anchor for Sanofi's double-digit top-line acceleration.
Pharma Launches Accelerating
The portfolio of new launches is accelerating, up 49.6% at CER to €1.17B. ALTUVIIIO (+42.2%) is dominating the hemophilia A market, driven by switches from legacy factor medicines. Sarclisa (+30.1%) is penetrating earlier lines of multiple myeloma treatment, particularly in Europe. This cohort is successfully diversifying Sanofi's growth engine beyond Dupixent.
Regeneron Profit-Sharing Squeezes Margins
A crucial contradiction exists in the income statement: Business gross profit grew a healthy 14.4% (CER), but Business Operating Income (BOI) margin compressed by 0.7 points (to 28.6%). The direct cause is a 62.4% surge in other operating expenses, primarily driven by the Regeneron alliance (-€1.38B net expense). As Dupixent sales soar, the corresponding profit share owed to Regeneron acts as a heavy anchor on operating leverage.
Vaccines Growth Decelerating
The vaccines segment managed only 2.1% growth (CER). Beyfortus U.S. sales reversed (-21.5%) entirely due to a high inventory build in the prior year. Additionally, flu and COVID-19 vaccines decelerated (-4.1%), highlighting the reliance on the Dynavax acquisition (Heplisav-B) to keep the broader segment in positive territory.
Macro Demographic Headwinds in China
Sanofi explicitly cited a macro demographic shift impacting results: sales of Polio/pertussis/hib (PPH) vaccines plummeted in the Rest of World segment (-13.1%), driven heavily by a decline in childbirths in China. Total China sales decreased 2.1%, reversing from previously stable growth, directly reflecting these demographic pressures.
Lunsekimig Nanobody Platform Validated
Sanofi reported positive Phase 2a/2b data for lunsekimig in asthma and CRSwNP. Lunsekimig uses a proprietary Nanobody platform designed to simultaneously block TSLP and IL13. While it missed the primary endpoint in a separate atopic dermatitis study, success in respiratory indications validates Sanofi's multi-specific antibody engineering pipeline.
R&D Cost Discipline
Despite a massive late-stage pipeline (12 Phase 3 readouts last year), Sanofi maintained strict R&D cost control. R&D expenses reached €1.75B, up only 1.5% at CER. This stable spending profile allows the company to fund innovation without aggressively eroding profitability.
Other KPIs
Stable. Up slightly (2.4%) from €1,029 million in 25Q1. Operating cash flows were sufficient to cover the €1.66B Dynavax acquisition alongside ongoing share repurchases, although net debt did increase sequentially to €12.9B.
Accelerating. Up 7.0% at CER, driven largely by SG&A increasing 11.6% due to the integration costs associated with the Blueprint and Dynavax acquisitions. This emphasizes the near-term margin dilution resulting from recent M&A.
Guidance
Decelerating. After delivering 13.6% CER growth in Q1, the full-year guidance implies a material slowdown in the remaining three quarters. This is likely due to tougher bases of comparison for Dupixent and the normalization of pharma launch curves.
Decelerating. Q1 Business EPS grew 14.0% (CER), so expecting full-year EPS to grow 'slightly faster' than high single-digits implies a deceleration. The heavy Regeneron profit-sharing drag and Blueprint/Dynavax integration costs will continue to weigh on the bottom line.
Key Questions
Regeneron Profit-Share Curve
Other operating expenses jumped 62% in Q1, significantly outpacing top-line growth. Can you provide a framework for when we should expect the Regeneron profit-share impact to plateau as a percentage of overall Dupixent sales?
Vaccines Demographic Strategy
With China's declining birth rates explicitly dragging down the PPH vaccine portfolio, how aggressively are you pivoting the global vaccines commercial strategy toward older adult immunizations, beyond the Heplisav-B acquisition?
Beyfortus Normalization
Beyfortus U.S. sales fell 21% due to prior-year inventory stocking. When do you expect U.S. purchasing patterns to normalize into a run-rate that accurately reflects underlying retail demand?
Lunsekimig Next Steps
Given lunsekimig's success in asthma but miss in AD, how are you prioritizing its Phase 3 development capital relative to amlitelimab, and will it be positioned primarily as a respiratory-only asset?